-
論文実績
-
2025年
発表者名 発表タイトル 学会名 金井雅史 切除不能胆道癌に対する個別化治療のパラダイムシフト 胆道 金井雅史 胆道癌薬物療法 免疫チェックポイント阻害薬 胆道 金井雅史 当院におけるがん医療開発を担う高度医療人材育成の取り組み 第８回 関西医科大学学術祭 栗岡 勇輔, 坂本 秀男, 朴 将源, 竹村 幸敏, 佐竹 悠良 大腸内視鏡生検標本を用いた患者由来腫瘍スフェロイドモデルの確立 日本大腸肛門病学会雑誌 Tetsushi Yamamoto, Shogen Boku, Kuniko Mitamura, Atsushi Taga Shotgun Label-Free Proteomic Analysis for Identification of a Potential Diagnostic Biomarker for Pancreatic Cancer. Biomedicines Tetsuhiro Yoshinami, Yuko Takano, Yukinori Ozaki, Yukiko Kajiwara, Mitsugu Yamamoto, Ken-ichi Watanabe, Masami Tsukabe, Fumie Fujisawa, Shigenori E. Nagai, Nobuhiro Shibata, Chiya Oshiro, Hiroko Bando, Nobuyuki Tsunoda, Kazuhiko Yamagami, Kei Koizumi, Masahiro Takada, Naoko Toriguchi, Nobuyuki Sekine, Tsutomu Kawaguchi, Shigehira Saji, Yasuaki Sagara, Satoshi Morita, Norikazu Masuda Real-world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first- or second-line treatment for hormone receptor–positive, HER2-negative advanced or metastatic breast cancer Breast cancer Kentaro Sawada, Riu Yamashita, Shunsuke A Sakai, Satoshi Horasawa, Ayumu Yoshikawa, Takao Fujisawa, Shigenori Kadowaki, Ken Kato, Makoto Ueno, Eiji Oki, Yoshito Komatsu, Tatsuyuki Chiyoda, Yosuke Horita, Hisateru Yasui, Tadamichi Denda, Hironaga Satake, Taito Esaki, Taroh Satoh, Naoki Takahashi, Kentaro Yamazaki, Nobuhisa Matsuhashi, Tomohiro Nishina, Hiroyuki Takeda, Koushiro Ohtsubo, Takashi Ohta, Akihito Tsuji, Masahiro Goto, Takeshi Kato, Hideaki Bando, Katsuya Tsuchihara, Yoshiaki Nakamura, Takayuki Yoshino Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study. Cancer research communications Akihito Kawazoe, Kensei Yamaguchi, Tetsuya Hamaguchi, Yukiya Narita, Shogen Boku, Takashi Oshima, Hiroki Hara, Yasuo Hamamoto, Kenji Ishido, Taito Esaki, Hisashi Hosaka, Hirofumi Yasui, Keisuke Koeda, Tomohiro Nishina, Yasushi Tsuji, Takeo Fukagawa, Masahiro Goto, Eiji Oki, Naotoshi Sugimoto, Hiroshi Matsuoka, Fumiharu Yokoyama, Tomoko Yoshida, Kazuo Yoshida, Yoshiaki Oshima, Satoru Iwasa ONO-4578 Plus Nivolumab in Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer. Cancer science 朴 将源 DEK-AFF2 fusion carcinomaにおけるpembrolizumab耐性メカニズムに対する考察 第62回日本癌治療学会学術集会 Tadayoshi Hashimoto, Naoko Iida, Yoshiaki Nakamura, Norio Nonomura, Chigusa Morizane, Hiroji Iwata, Susumu Okano, Wataru Yamagami, Naoya Yamazaki, Shigenori Kadowaki, Makoto Ueno, Shogen Boku, Eiji Oki, Yoshito Komatsu, Satoshi Yuki, Akitaka Makiyama, Takatsugu Ogata, Naoki Takahashi, Naohiro Okano, Tomohiro Nishina, Naoya Sakamoto, Takeshi Kuwata, Riu Yamashita, Taro Shibuki, Mitsuho Imai, Takao Fujisawa, Hideaki Bando, Kohei Shitara, Takayuki Yoshino Landscape Analysis of CLDN18 Expression and Isoform Distribution in Solid Tumors: Insights From MONSTAR-SCREEN-2 Study. Cancer science Shogen Boku, Tatsuki Ikoma, Tomoyo Yasuda, Nobuhiro Shibata, Tomofumi Sakagami, Kensuke Suzuki, Takuo Fujisawa, Hiroshi Iwai, Masashi Kanai Relationship between the effectiveness of pembrolizumab monotherapy and ABO blood type in recurrent and metastatic squamous cell carcinoma of the head and neck. Discover oncology T Hashimoto, N Iida, S Kadowaki, A Makiyama, N Machida, N Takahashi, S Boku, T Kudo, E Oki, K Ohtsubo, T Kawakami, N Okano, Y Komatsu, S Yuki, N Sakamoto, T Kuwata, R Yamashita, M Amisaki, T Shibuki, M Imai, T Fujisawa, Y Nakamura, H Bando, K Shitara, T Yoshino FGFR2-IIIc isoform detection reveals prognostic prevalence and a functional link to mesenchymal transition in gastric and gastroesophageal junction cancer. ESMO open Shogen Boku, Hironaga Satake, Seiichiro Mitani, Kiyoshi Maeda, Toshihiro Kudo, Toshifumi Yamaguchi, Tatsuya Takagi, Hisato Kawakami A placebo-controlled study of the doses and efficacy of Lentinula edodes mycelia for oxaliplatin-induced peripheral neuropathy in colorectal cancer. Frontiers in oncology Hiroki Yukami, Toshifumi Yamaguchi, Shunji Endo, Shogen Boku, Yukinori Kurokawa, Toshimasa Tsujinaka, Toshio Shimokawa, Taroh Satoh ASTRON (OGSG 2401) study protocol: Ferric carboxymaltose for iron deficiency anemia in gastrointestinal cancer. Future oncology (London, England) Ryohei Kawabata, Daisuke Sakai, Toshio Shimokawa, Rika Kizawa, Toru Ishiguro, Hiroki Yukami, Shogen Boku, Toshifumi Yamaguchi, Shunji Endo, Toshimasa Tsujinaka, Taroh Satoh Efficacy and safety of irinotecan-based therapy in elderly patients with advanced gastric cancer receiving third-line or later chemotherapy: post-hoc age-subgroup analysis of the rindberg trial. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association M Nomura, M Yoshimura, T Yokota, S Boku, I Oze, H Ishikawa, M Muto Phase II trial on nivolumab plus hypofractionated radiotherapy in patients with metastatic mucosal melanoma: PORTER-M3 trial. Immuno-oncology technology Shogen Boku, Tomoyo Yasuda, Tatsuki Ikoma, Eri Matsumori, Sawako Yoshiuchi, Yoshiyuki Matsuo, Koichiro Higasa, Takayasu Kurata Anamorelin in Cancer Cachexia: Gut Microbiota Effects and CONUT Score as a Predictor of Response. In vivo (Athens, Greece) Shogen Boku, Takao Fujisawa, Shigenori Kadowaki, Hironaga Satake, Hisateru Yasui, Koushiro Ohtsubo, Yasushi Shimizu, Tomoyuki Otsuka, Bunya Kuze, Riu Yamashita, Taro Shibuki, Yoshiaki Nakamura, Hideaki Bando, Takayuki Yoshino, Milan Radovich, Susumu Okano Resistance mechanism to pembrolizumab in DEK-AFF2 fusion-associated sinonasal squamous cell carcinoma. International cancer conference journal Hiroyuki Matsubayashi, Chigusa Morizane, Masashi Kanai, Yoshimi Kiyozumi, Masayuki Kitano Diagnosis and treatment strategies for hereditary pancreatic cancer syndrome. International journal of clinical oncology Hisateru Yasui, Masaki Aizawa, Kensei Yamaguchi, Akihito Kawazoe, Hiroki Hara, Masahiro Tsuda, Hirokazu Shoji, Naotoshi Sugimoto, Nobuhiro Shibata, Kenji Amagai, Yasuhiro Choda, Shiro Iwagami, Taito Esaki, Shigenori Kadowaki, Shinichi Shiratori, Shirong Han, Sonal Bordia, Kohei Shitara First-line pembrolizumab plus chemotherapy for participants in Japan with gastric or gastroesophageal junction adenocarcinoma: subgroup analysis of the phase 3 KEYNOTE-859 study. International journal of clinical oncology Fujisawa T, Nakamura Y, Bando H, Morizane C, Ikeda M, Nonomura N, Matsubara N, Iwata H, Naito Y, Okano S, Aoki D, Harano K, Yamazaki N, Namikawa K, Ueno M, Kadowaki S, Oki E, Kato K, Komatsu Y, Satoh T, Esaki T, Denda T, Hamaguchi T, Yamazaki K, Matsuhashi N, Yasui H, Satake H, Nishina T, Takahashi N, Goto M, Sunakawa Y, Kato T, Otsuka T, Abutani H, Tukachinsky H, Lee JK, Oxnard GR, Kuramoto N, Horasawa S, Sakamoto Y, Taniguchi H, Yoshino T. Benefits of Combining Circulating Tumor DNA With Tissue and Longitudinal Circulating Tumor DNA Genotyping in Advanced Solid Tumors: SCRUM-Japan MONSTAR-SCREEN-1 Study JCO Precision Oncology Michiko Nagamine, Takao Fujisawa, Naoya Sakamoto, Yoshiaki Nakamura, Shigenori Kadowaki, Makoto Ueno, Shogen Boku, Yoshito Komatsu, Eiji Oki, Akitaka Makiyama, Norio Nonomura, Chigusa Morizane, Hidemichi Watari, Susumu Okano, Hiroji Iwata, Kenjiro Namikawa, Yutaka Hatanaka, Kanako C Hatanaka, Kenichi Taguchi, David Spetzler, Milan Radovich, Daniel Magee, Takayuki Yoshino, Matthew Oberley, Takeshi Kuwata HER2 Protein Overexpression, mRNA Expression, and DNA Amplification Across Solid Tumors: Comparison of Next-Generation Sequencing-Based Assays With Immunohistochemistry. JCO precision oncology Yoshiaki Nagatani, Naomi Kiyota, Tomoko Yamazaki, Yukinori Asada, Masaaki Higashino, Hironaga Satake, Shogen Boku, Ari Nishimura, Hirokazu Uemura, Ichiro Ota, Katsunari Yane, Kaoru Tanaka, Takuma Onoe, Yuji Hirayama, Takahiro Tsujikawa, Hajime Fujiwara, Hikari Shimoda, Ken-Ichi Nibu, Yoshinori Imamura, Shiro Kimbara, Taiji Koyama, Yohei Funakoshi, Hironobu Minami A phase II trial of nivolumab for patients with platinum-refractory recurrent or metastatic salivary gland cancer. Japanese journal of clinical oncology Daisuke Sakai, Shigenori Kadowaki, Ryohei Kawabata, Hiroki Hara, Hironaga Satake, Masazumi Takahashi, Atsushi Takeno, Hiroo Imai, Keiko Minashi, Takeshi Kawakami, Shogen Boku, Jin Matsuyama, Yasuhiro Sakamoto, Kentaro Sawada, Masato Kataoka, Hisato Kawakami, Toshio Shimokawa, Narikazu Boku, Taroh Satoh Randomized Phase III Trial of Ramucirumab Beyond Progression Plus Irinotecan in Patients With Ramucirumab-Refractory Advanced Gastric Cancer: RINDBeRG Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology Okazawa-Sakai M, Sakai SA, Hyodo I, Horasawa S, Sawada K, Fujisawa T, Yamamoto Y, Boku S, Hayasaki Y, Isobe M, Shintani D, Hasegawa K, Egawa-Takata T, Ito K, Ihira K, Watari H, Takehara K, Yagi H, Kato K, Chiyoda T, Harano K, Nakamura Y, Yamashita R, Yoshino T, Aoki D. Gut microbiome associated with PARP inhibitor efficacy in patients with ovarian cancer Journal of gynecologic oncology Satoshi Ogiso, Etsuro Hatano, Satoru Seo, Masashi Kanai, Shogo Kobayashi, Hiroshi Wada, Hidetoshi Eguchi, Tatsuya Higashi, Hiroaki Nagano, Tatsuya Ioka Neoadjuvant Chemotherapy With Gemcitabine/Cisplatin/S-1 for Resectable Biliary Tract Cancer With FDG-PET-Positive Lymph Node Metastasis (KHBO1201): A Multicenter Phase II Trial. Journal of hepato-biliary-pancreatic sciences Lisa M Wintner, Monika Sztankay, Hikmat Abdel-Razeq, Renad Hamdan-Mansour, Giovanni Caocci, Guillaume Mouillet, Yuichiro Kikawa, Nobuhiro Shibata, Manjunath Nookala Krishnamurthy, Amit Joshi, Rahul Krishnatry, Aditi Jain, Helle Pappot, Duska Petranovic, Antonela Trobentar, Heike Schmidt, Susann Schulze, Anastasia Tararykova, August Zabernigg, Johannes M Giesinger, Bernhard Holzner, on behalf of the EORTC Quality of Life Group Inter-rater reliability of CTCAE assessments with or without EORTC patient-reported outcome data in a mixed cancer population: a multinational, open-label, randomised controlled trial The Lancet Oncology Toshihiko Matsumoto, Tatsuki Ikoma, Chinatsu Makiyama, Tomoyo Yasuda, Shogen Boku, Akio Nakasya, Nobuhiro Shibata, Hiroki Nagai, Takao Tsuduki, Yusuke Matsumoto, Hisateru Yasui, Reiji Higashi, Akitoshi Sasamoto, Hironaga Satake, Kentaro Inoue, Masashi Kanai, Makoto Yamasaki Efficacy and safety of taxane plus ramucirumab for advanced gastric cancer after chemotherapy plus nivolumab. Scientific reports Tetsuhiro Yoshinami, Nobuhiro Shibata, Kentaro Tamaki, Kentaro Ishimaru, Satoru Ito, Tomoyuki Nukada, Shinji Ohno Real-world evidence of febrile neutropenia-related hospitalization on patients with perioperative chemotherapy for early breast cancer in Japan Breast cancer Kazuhiro Ko, Mayu Fukuda, Koji Yamanoi, Nobutaka Hayashi, Hisateru Yasui, Takuma Hayashi, Yoshihiro Yakushijin, Takehiko Tsumura, Atsushi Shirakawa, Chiho Nakajima, Eiju Negoro, Chikako Yamauchi, Toshio Shimizu, Takahito Ashihara, Nobuhiro Shibata, Takeshi Kotake, Aya Toyofuku, Taito Miyamoto, Rin Mizuno, Mana Taki, Ryusuke Murakami, Satoshi Morita, Manabu Muto and Masaki Mandai Real-world multicenter study of immune checkpoint inhibitors in advanced cervical cancer across HPV-associated and HPV-independent subtypes International journal of clinical oncology Yuqing Duan, Tadayoshi Hashimoto, Taro Shibuki, Hiroya Taniguchi, Yu Sunakawa, Yoshito Komatsu, Naoki Takahashi, Yuta Sato, Kensei Yamaguchi, Tomohiro Nishina, Tomonori Nakanoko, Shogen Boku, Taroh Satoh, Hisateru Yasui, Taito Esaki, Mitsuho Imai, Takao Fujisawa, Yoshiaki Nakamura, Hideaki Bando, Takayuki Yoshino Prognostic Biomarkers and Immunotherapeutic Insights of Circulating Tumor DNA Analysis in Advanced Esophageal Squamous Cell Carcinoma From SCRUM-MONSTAR GOZILA Substudy. JCO precision oncology Nodoka Umezaki, Shogen Boku, Yoshiyuki Matsuo, Tetsushi Yamamoto, Hironaga Satake, Motoki Watanabe, Kiichi Hirota, Tomoharu Sugie, Mitsugu Sekimoto Hypoxia and aspirin additively increase intracellular glutamine accumulation in PIK3CA-mutated colorectal cancer cells. Scientific reports Motoki Watanabe, Shogen Boku, Mamiko Sukeno, Kaito Kobayashi, Tomoshi Kameda, Yosuke Iizumi, Wataru Nishio, Michihiro Mutoh, Toshiyuki Sakai Caffeic acid suppresses cyclin D1 expression by directly binding to ribosomal protein S5 in colorectal cancer cells. Scientific reports Nobuhiro Shibata, Hiroshi Kuwazawa, Tomoharu Yasukawa, Manabu Iwabuchi, Shigehira Saji The safety and effectiveness of pegfilgrastim to reduce cancer chemotherapy-induced febrile neutropenia in real-world practice in Japan: a post-marketing surveillance study. Supportive care in cancer -
2024年
Hashimoto D, Satoi S, Yamaki S, Nakayama S, Shibata N, Matsumura K, Miyazaki H, Matsui Y, Tsybulskyi D, Sang NT, Ikeura T, Kanai M, Sekimoto M.,2025/01,Neoadjuvant Treatment with Changes in Chemotherapy Regimens According to Carbohydrate Antigen 19-9 Level for Resectable/Borderline Resectable Pancreatic Ductal Adenocarcinoma,Annals of surgical oncology,Ann Surg Oncol,32(1):517-528,10.1245/s10434-024-16361-y,39433718
Hashimoto T, Nakamura Y, Komatsu Y, Yuki S, Takahashi N, Okano N, Hirano H, Ohtsubo K, Ohta T, Oki E, Nishina T, Yasui H, Kawakami H, Esaki T, Machida N, Doi A, Boku S, Kudo T, Yamamoto Y, Kanazawa A, Denda T, Goto M, Iida N, Ozaki H, Shibuki T, Imai M, Fujisawa T, Bando H, Naito Y, Yoshino T.,2024/07,Different efficacy of tyrosine kinase inhibitors by KIT and PGFRA mutations identified in circulating tumor DNA for the treatment of refractory gastrointestinal stromal tumors,BJC reports,BJC Rep,2(1):54,10.1038/s44276-024-00073-7,39516322
Kato C, Iizuka-Ohashi M, Honda M, Konishi E, Yokota I, Boku S, Mizuta N, Morita M, Sakaguchi K, Taguchi T, Watanabe M, Naoi Y.,2024/12,Additional statin treatment enhances the efficacy of HER2 blockade and improves prognosis in Rac1-high/HER2-positive breast cancer,Biochimica et biophysica acta. Molecular basis of disease,Biochim Biophys Acta Mol Basis Dis,1870(8):167458,10.1016/j.bbadis.2024.167458,39128642
Takahiro Nakayama, Naoki Niikura, Takashi Yamanaka, Mitsugu Yamamoto, Kazuo Matsuura, Kenichi Inoue, Sachiko Takahara, Hironori Nomura, Shosuke Kita, Miki Yamaguchi, Tomoyuki Aruga, Nobuhiro Shibata, Akihiko Shimomura1, Yuri Ozaki, Shuji Sakai, Daisuke Takiguchi, Takehiko Takata, Armin Bastanfard, Kazuhito Shiosakai, Junji Tsurutani,2024/11,Trastuzumab deruxtecan for the treatment of patients with HER2‑positive breast cancer with brain and/or leptomeningeal metastases: an updated overall survival analysis using data from a multicenter retrospective study (ROSET‑BM),Breast cancer,Breast Cancer,31(6):1167-1175,10.1007/s12282-024-01614-1,39133378
Hashimoto T, Nakamura Y, Fujisawa T, Imai M, Shibuki T, Iida N, Ozaki H, Nonomura N, Morizane C, Iwata H, Okano S, Yamagami W, Yamazaki N, Kadowaki S, Taniguchi H, Ueno M, Boku S, Oki E, Komatsu Y, Yuki S, Makiyama A, Otsuka T, Hara H, Okano N, Nishina T, Sakamoto Y, Miki I, Kobayashi S, Yuda J, Kageyama SI, Nagamine M, Sakashita S, Sakamoto N, Yamashita R, Koga Y, Bando H, Ishii G, Kuwata T, Park WY, Ohtsu A, Yoshino T.,2024/11,The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine,Cancer discovery,Cancer Discov,14(11):2243-2261,10.1158/2159-8290.CD-24-0206,39023403
Ikoma T, Matsumoto T, Boku S, Motoki Y, Kinoshita H, Kosaka H, Kaibori M, Inoue K, Sekimoto M, Fujisawa T, Iwai H, Naganuma M, Tanizaki H, Hisamatsu Y, Okada H, Kurata T.,2024/05,Safety of immune checkpoint inhibitors in patients aged over 80 years: a retrospective cohort study,Cancer immunology, immunotherapy : CII,Cancer Immunol Immunother,73(7):126,10.1007/s00262-024-03707-4,38733406
Kanai M.,2025/02,Challenges and Opportunities for the Clinical Application of the Combination of Immune-Checkpoint Inhibitors and Radiation Therapy in the Treatment of Advanced Pancreatic Cancer,Cancers,Cancers (Basel),17(4):606,10.3390/cancers17040606,40002201
Iida N, Imai M, Okamoto W, Kato T, Esaki T, Kato K, Komatsu Y, Yuki S, Masuishi T, Nishina T, Ebi H, Taniguchi H, Nonomura N, Sunakawa Y, Shiozawa M, Yamazaki K, Boku S, Bando H, Shiraishi Y, Kobayashi M, Goto H, Sato A, Fujii S, Yoshino T, Nakamura Y.,2024/09,Novel ERBB2 Variant Potentially Associated with Resistance against Anti-HER2 Monoclonal Antibody-Based Therapy in ERBB2-Amplified Metastatic Colorectal Cancer,Clinical cancer research,Clin Cancer Res,30(18):4167-4178,10.1158/1078-0432.CCR-24-1023,39163021
Honma Y, Monden N, Yamazaki K, Kano S, Satake H, Kadowaki S, Utsumi Y, Nakatogawa T, Takano R, Fujii K, Koroki Y, Aoyama J, Ouchi S, Ogawa T, McCarthy S, Brookman-May SD, Mundle S, Li J, Thaper D, Nagao T, Tada Y.,2024/08,Apalutamide and Goserelin for Androgen Receptor-Positive Salivary Gland Carcinoma: A Phase 2 Nonrandomized Clinical Trial, YATAGARASU,Clinical cancer research,Clin Cancer Res,30(16):3416-3427,10.1158/1078-0432.CCR-24-0455,38940667
Koyama T, Kiyota N, Boku S, Imamura Y, Shibata N, Satake H, Tanaka K, Hayashi H, Onoe T, Asada Y, Yamazaki T, Nose T, Ohata S, Nagatani Y, Kimbara S, Funakoshi Y, Teshima M, Shinomiya H, Minami H.,2024/06,A phase II trial of paclitaxel plus biweekly cetuximab for patients with recurrent or metastatic head and neck cancer previously treated with both platinum-based chemotherapy and anti-PD-1 antibody,ESMO open,ESMO open,9(6):103476,10.1016/j.esmoop.2024.103476,38833968
Nakao T, Shindo T, Takakura H, Narita T, Ise-Nakao Y, Akiyama S, Iizumi Y, Boku S, Watanabe M, Sakai T, Shimizu S, Yamada M, Sowa Y, Mutoh M.,2025/02,Trametinib Suppresses the Stimulated T Cells Through G1 Arrest and Apoptosis,European journal of immunology,Eur J Immunol,55(2):e202350667,10.1002/eji.202350667,39989249
Kataoka K, Ouchi A, Suwa Y, Hirano H, Yamaguchi T, Takamizawa Y, Hanaoka M, Iguchi K, Boku S, Nagata K, Koyama T, Shimada Y, Inomata M, Sano Y, Mizusawa J, Hamaguchi T, Takii Y, Tsukamoto S, Takashima A, Kanemitsu Y; JCOG Colorectal Cancer Study Group.,2024/06,Localized colorectal cancer database integrating 4 randomized controlled trials; (JCOG2310A),European journal of surgical oncology,Eur J Surg Oncol,50(6):108354,10.1016/j.ejso.2024.108354,38657376
Ando K, Satake H, Shimokawa M, Yasui H, Negoro Y, Kinjo T, Kizaki J, Baba K, Orita H, Hirata K, Sakamoto S, Makiyama A, Saeki H, Tsuji A, Baba H, Oki E.,2025/03,A phase two trial evaluating FOLFIRI plus aflibercept after failure of FOLFOXIRI plus bevacizumab in patients with unresectable metastatic colorectal cancer,International journal of clinical oncology,Int J Clin Oncol,30(3):514-523,10.1007/s10147-025-02701-9,39891883
Hamada M, Matsumi Y, Inada R, Matsumoto T, Kita M, Boku S, Kurokawa H, Tsuta K.,2025/03,MRI navigation surgery for T4b rectal cancer using multiple minimally invasive surgical approaches,International journal of colorectal disease,Int J Colorectal Dis,40(1):66,10.1007/s00384-025-04838-5,40085244
Sano Y, Kanai M, Morizane C, Sasaki K, Yoshimura M, Ito Y, Furuse J, Ozaka M, Fukuda H, Ueno M; Hepatobiliary and Pancreatic Oncology Group in Japan Clinical Oncology Group.,2024/11,Protocol digest of a randomized phase III trial comparing S-1-based chemoradiotherapy with/without nivolumab for unresectable locally advanced or borderline resectable pancreatic cancer: JCOG1908E (PENETRATE),Japanese journal of clinical oncology,Jpn J Clin Oncol,54(11):1214-1218,10.1093/jjco/hyae084,38941345
Shimada S, Yamada T, Minamoto A, Matsukawa M, Yabe I, Tada H, Oda K, Ueki A, Higashigawa S, Morikawa M, Sato Y, Hirasawa A, Ogawa M, Kondo T, Yoshioka M, Kanai M, Muto M, Kosugi S.,2025/01,Nationwide survey of the secondary findings in cancer genomic profiling: survey including liquid biopsy,Journal of human genetics,J Hum Genet,70(1):33-40,10.1038/s10038-024-01294-x,39289525
Kataoka K, Yamada T, Shiozawa M, Takase N, Ito K, Yamazaki K, Watanabe J, Kudo T, Suto T, Matsumoto T, Murata K, Suwa Y, Boku S, Yasui H, Matsuhashi N, Maeda A, Sugimoto K, Matsumoto Y, Yokota M, Fredebohm J, Mori K, Ikeda M.,2024/04,Monitoring ctDNA RAS Mutational Status in Metastatic Colorectal Cancer: A Trial Protocol of RAS-trace and RAS-trace-2 Studies,Journal of the anus, rectum and colon,J Anus Rectum Colon,8(2):132-136,10.23922/jarc.2023-051,38689780
Bando H, Kotani D, Satake H, Hamaguchi T, Shiozawa M, Kotaka M, Masuishi T, Yasui H, Kagawa Y, Komatsu Y, Oki E, Yamamoto Y, Kawakami H, Misumi T, Taniguchi H, Yamazaki K, Muro K, Yoshino T, Kato T, Tsuji A.,2024/09,QUATTRO-II randomized trial: CAPOXIRI+bevacizumab vs. FOLFOXIRI+bevacizumab as first-line treatment in patients with mCRC,Med (New York, N.Y.),Med,5(9):1164-1177,10.1016/j.medj.2024.05.012,38901425
Nakamura Y, Ozaki H, Ueno M, Komatsu Y, Yuki S, Esaki T, Taniguchi H, Sunakawa Y, Yamaguchi K, Kato K, Denda T, Nishina T, Takahashi N, Satoh T, Yasui H, Satake H, Oki E, Kato T, Ohta T, Matsuhashi N, Goto M, Okano N, Ohtsubo K, Yamazaki K, Yamashita R, Iida N, Yuasa M, Bando H, Yoshino T.,2025/01,Targeted therapy guided by circulating tumor DNA analysis in advanced gastrointestinal tumors,Nature medicine,Nat Med,31(1):165-175,10.1038/s41591-024-03244-8,39284955
Kobayashi S, Wada H, Sakai D, Baba H, Kanai M, Kamachi H, Takayama T, Ueno M, Takahashi M, Sho M, Yoshimura K, Hatano E, Nagano H, & Ioka T,2024/10,Impact of Tumor Shrinkage Pattern with Biweekly Triplet Gemcitabine+Cisplatin+S-1 Regimen for Biliary Tract Cancers: Implications for Neoadjuvant Therapy from the Data of KHBO1401 (KHBO1401-1A Study),Oncology,Oncology,102(6):447-456,10.1159/000533669,38048759
Shibuki T, Ikeda M, Yokoyama M, Sano Y, Furuse J, Kobayashi S, Ohba A, Todaka A, Horie Y, Shioji K, Kanai M, Nishina T, Kumamoto Y, Fujimori N, Katanuma A, Takayama Y, Tsumura H, Miwa H, Ozaka M, Ueno M.,2025/03,Depth of response in patients with locally advanced pancreatic cancer treated with first-line chemotherapy: A supplementary analysis of JCOG1407,Pancreatology,Pancreatology,25(2):275-283,10.1016/j.pan.2025.02.005,39984379
Maruo M, Ikeura T, Takaori A, Ikeda M, Nakamaru K, Ito T, Masuda M, Mitsuyama T, Nakayama S, Shimatani M, Takaoka M, Shibata N, Boku S, Yasuda T, Miyazaki H, Matsumura K, Yamaki S, Hashimoto D, Satoi S, Naganuma M.,2024/08,Impact of endoscopic ultrasound-guided tissue acquisition on prognosis and peritoneal lavage cytology in resectable or borderline resectable pancreatic ductal adenocarcinoma,Pancreatology,Pancreatology,24(5):787-795,10.1016/j.pan.2024.06.001,38871559
Shiraishi K, Okada M, Yamamoto S, Matsubara Y, Masuishi T, Shimozaki K, Yamamoto Y, Hirose S, Sugiyama K, Furuta M, Machida N, Takahashi N, Yoshii T, Kito Y, Tsuzuki T, Boku S, Tsuchihashi K, Sugaya A, Takayama T, Komori A, Mitani S, Matsumoto T, Nishimura T, Hirata K.,2025/03,The efficacy and safety of FOLFOX therapy for advanced esophageal squamous cell carcinoma,Scientific reports,Sci Rep,15(1):8031,10.1038/s41598-025-92657-7,40055515
Shibuki T, Ikeda M, Yokoyama M, Sano Y, Furuse J, Kobayashi S, Ohba A, Todaka A, Horie Y, Shioji K, Kanai M, Nishina T, Kumamoto Y, Fujimori N, Katanuma A, Takayama Y, Tsumura H, Miwa H, Ozaka M, & Ueno M.,2025/02,Colorectal cancer harboring EGFR kinase domain duplication response to EGFR tyrosine kinase inhibitors,The Oncologist,Oncologist,30(2):oyae113,10.1093/oncolo/oyae113,38821532
-
2025年
-
国内外の学会発表
- 2025年
-
2024年
発表者名 発表タイトル 学会名 金井雅史 腫瘍生物学II：分子標的とがん治療 第22回日本臨床腫瘍学会学術集会 金井雅史 多様化するゲノム検査をどう使い分けるか 第22回日本臨床腫瘍学会学術集会 金井雅史 当院におけるがん医療開発を担う高度医療人材育成の取り組み 第８回 関西医科大学学術祭 金井雅史 第4回エキパネ道場 第4回エキパネ道場 日本臨床腫瘍学会 金井雅史 胆道癌薬物療法の最前線~リトゴビデータの紹介と位置づけ~ 第60回日本胆道学会学術集会 ランチョンセミナー 金井雅史 胆道癌薬物療法 免疫チェックポイント阻害薬 第60回日本胆道学会学術集会 指導医養成講座オンデマンド配信 安田知代 切除不能/再発食道癌に対する5FU+CDDP+ICIの悪性狭窄改善効果 第62回日本癌治療学会 安田 知代 食道癌の集学的治療～高齢化社会とICI時代の先鞭をつける～切除不能/再発食道癌に対する5FU+CDDP+ICIの悪性狭窄改善効果 第62回日本癌治療学会学術集会 朴 将源 DEK-AFF2 fusion carcinomaにおけるpembrolizumab耐性メカニズムに対する考察 第62回日本癌治療学会学術集会 金井雅史 免疫チェックポイント阻害薬導入における胆道癌の新たな治療戦略~1年半の使用経験からの学び~ 日本消化器病学会近畿支部第121回例会 ランチョンセミナー 金井雅史 膵癌の長期予後向上を目指して－切除不能膵癌の最先端治療 第55回膵臓病学会大会 柴田伸弘 早期Triple negative breast cancerに対するKYENOTE-522レジメンの治療成績 第32回日本乳癌学会 安田知代 当院における進行食道癌5FU+CDDP+ICIの治療成績～狭窄症状改善の観点から～ 第78回日本食道学会 金井雅史 治癒切除不能胆道癌の新たな薬物療法~KEYNOTE-966試験を読み解く~ 第36回 日本肝胆膵外科学会学術集会 金井雅史 ここまで進んだがんゲノム医療 第29回日本緩和医療学会学術集会/第37回日本サイコオンコロジー学会総会 合同学術集会 朴 将源 プラチナ製剤および抗PD-1抗体薬既治療頭頸部がんに対するパクリタキセル+隔週セツキシマブの第2相試験 第48回日本頭頚部癌学会
-
研究助成金獲得
-
2025年
金井雅史 AMED「薬剤耐性と副作用の克服を目指した多発性骨髄腫に対するプロドラッグ型抗がん薬TBP1901の前臨床研究」 科研費「オキサリプラチンの至適投与法に関する研究」 朴将源 AMED「患者由来がん幹細胞培養を基盤とした革新的個別化医療開発」
-
2025年
関西医科大学附属病院 臨床腫瘍科
Clinical Oncology Kansai Medical University Hospital